Esperion out to raise $150M; Acucela to hold shareholders meeting as founder fights for control;

@FierceBiotech: ICYMI yesterday: Struggling GlaxoSmithKline warns of 150 R&D job cuts in Philadelphia. News | Follow @FierceBiotech

@JohnCFierce: Pfizer joins a powerhouse syndicate backing $43M round for Nimbus. News | Follow @JohnCFierce

@DamianFierce: Dear Twitter, it is my great honor to introduce FierceMadness, the 2015 Drug Name Tournament. Check it out | Follow @DamianFierce

> Shortly after Esperion ($ESPR) rolled out positive data on its cholesterol-lowering drug, the biotech announced plans to raise about $150 million through a stock sale. Release

> Seattle-based Acucela was ordered to hold a special shareholders meeting May 1 as founder Ryo Kubota pursued his quest to regain control of the biotech. Story

> Ignyta ($RXDX) is buying four in-development cancer drugs from Teva ($TEVA) in exchange for a 1.5 million shares, a 6% stake in the company. Under the deal, Teva is committing to buy another 1.5 million Ignyta shares at $10 each. More

> Y Combinator startup Ginkgo Bioworks raised a $9 million Series A to support its efforts to custom engineer organisms. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Mayo Clinic finds a common MRI contrast agent is deposited in the brain. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Tablets, apps being deployed to improve customer service in the ICU. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT and the University of Minnesota are studying hibernating bears to gain insight into treating heart disease. More | Follow @EmilyWFierce

> Olympus faces more legal pushback over endoscopes linked to UCLA superbug outbreak. Article

> Vivo Capital doubles down to close $750M U.S.-China healthcare fund. Story

> Boston Scientific implantable defibrillator gets FDA green light. Report

Pharma News

@FiercePharma: Sinovac close to China marketing approval for hand, foot and mouth vaccine. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Malaysia's CCM Duopharma Biotech ready to compete with the big boys, buying 6 plants from parent. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market. Article | Follow @CarlyHFierce

> England's Cancer Drugs Fund changes its tune, holds onto Novartis' Afinitor. Story

> Gilead to require proof of citizenship to buy Sovaldi in poor countries. Report

Biotech Research News

> Research group uses nanoparticles to deliver antibiotic. Item

> Fast-spreading CRISPR tech inspires new preclinical work on blood cancers. More

> Academic team assembles a 'homegrown' immunotoxin for blood cancers. Story

> Blood pressure drug looks promising in preventing myelin loss in MS. Article

> Rockefeller U team touts a potential psoriasis 'cure' from Boehringer. Report

Diagnostics News

> Metabolon rides on last year's success with $5M in extended financing. Story

> Illumina hits U.K. company with prenatal test patent suit. Article

> Myriad extends collaboration with BioMarin for cancer companion Dx. Item

> Invitae to focus on adding genetic tests, securing reimbursement in 2015. Report

> 23andMe launches new therapeutics group with biotech vet taking the reins. More

Pharma Marketing News

> Worried about quality at home, Chinese consumers stock up on 'Made in Japan' drugs. Item

> Judge tosses Xolair kickback suit against Novartis, Genentech. Report

> Pernix looks for a sales trifecta from 100 new Zohydro reps. Story

> Mayo docs join the revolt against rising cancer drug prices. News

> It had to happen: Apple Watch gets a drug-adherence app. More

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.